Neurophilosophy

Mood stabilizers have been approved by the Food and Drug Administration (FDA) for at least one of 3 phases of bipolar disorder (mania, bipolar depression, long term survival).However, no drug, including mood stabilizers, has been approved by the FDA for the treatment of BPD. Only use of mood stabilizers in some symptoms is recommended. This suggests that the presence of BPD in the bipolar spectrum does not make much sense in terms of treatment.Psychotherapeutic approaches, which can be regarded as psychosocial treatments, give hope in spite of the inadequate data on the treatment of CBF with mood stabilizers.Psychotherapeutic approaches, which can be regarded as psychosocial treatments, give hope in spite of the inadequate data on the treatment of BPD with mood stabilizers. Among these approaches; Dialectical behavioral therapy, schema-focused therapy, and transfer-focused psychotherapies. As you can see, the efforts of the BPD to insist on placing bipolar disorders between places do not make a serious contribution to the treatment approach. Significant overlap of the diagnostic criteria in the DSM system does not mean that both disorder groups are exactly the same thing. However, it is a fact that it is not easy to distinguish bipolar disorders other than bipolar I disorder by BPD. Only inadequate decomposition efforts to be performed according to the diagnostic criteria in the DSM system are inadequate. It may also be beneficial from a treatment point of view to provide a more comprehensive assessment and resolution.